AC Immune SA
AC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with four product candidates in clinical trials.
The Company designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. AC Immune‘s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as Alzheimer‘s disease.
The Company‘s pipeline features seven therapeutic and three diagnostic product candidates. The most advanced of these is Crenezumab, an anti-Abetaantibody in Phase 3 clinical studies that is being advanced by the collaboration partner Genentech,Inc., a member of the Roche Group. Other business partners include Biogen, Janssen Pharmaceuticals, Nestlè Institute of Health Sciences and PiramalImaging.